ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Inc. (OTCBB:INSV) today announced that the Company has received a second unsolicited proposal from a global pharmaceutical company to acquire all outstanding shares of InSite Vision common stock at an increased price of $0.35 per share in cash. The proposal is only subject to due diligence regarding the recently filed BromSite™ patent lawsuit. InSite Vision believes the lawsuit is without merit.
Help employers find you! Check out all the jobs and post your resume.
